| Date Filed | Type | Description |
| 05/04/2023 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 45,643 options to buy
@ $117.89, valued at
$5.4M
|
|
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 01/25/2023 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 17,495 shares
@ $109.88, valued at
$1.9M
|
|
| 01/11/2023 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 83,994 shares
@ $53.06, valued at
$4.5M
Sold 35,598 shares
@ $110.6146, valued at
$3.9M
Sold 4,538 shares
@ $111.7339, valued at
$507k
Sold 3,940 shares
@ $112.7823, valued at
$444.4k
Sold 38,216 shares
@ $113.7752, valued at
$4.3M
Sold 1,702 shares
@ $114.4612, valued at
$194.8k
Exercised 83,994 options to buy
@ $0 |
|
| 05/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2021 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Sold 24,619 shares
@ $87.32, valued at
$2.1M
Exercised 24,619 options to buy
@ $0 |
|
| 05/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/17/2020 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Sold 10,380 shares
@ $83.0131, valued at
$861.7k
|
|
| 05/05/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/07/2019 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 64,922 options to buy
@ $80, valued at
$5.2M
|
|
| 02/27/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/14/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/06/2018 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Sold 29,208 shares
@ $65.2, valued at
$1.9M
Exercised 10,000 options to buy
@ $37.49, valued at
$374.9k
Exercised 19,208 options to buy
@ $33.49, valued at
$643.3k
|
|
| 05/08/2018 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 65,872 options to buy
@ $57.75, valued at
$3.8M
|
|
| 05/02/2018 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 4,009 shares
@ $0
Paid exercise price by delivering 1,142 shares
@ $58.87, valued at
$67.2k
Exercised 4,009 restricted stock units
@ $58.87, valued at
$236k
|
|
| 03/01/2018 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 4,522 shares
@ $54.72, valued at
$247.4k
|
|
| 11/13/2017 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Unknown transaction of 13,100 options to buy
@ $56.21, valued at
$736.3k
|
|
| 05/09/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/03/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/01/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 08/03/2016 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 5,150 shares
@ $0
Paid exercise price by delivering 1,619 shares
@ $58.66, valued at
$95k
Exercised 5,150 restricted stock units
@ $58.66, valued at
$302.1k
|
|
| 05/12/2016 |
4
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 81,494 options to buy
@ $54.68, valued at
$4.5M
|
|
| 04/08/2016 |
3
| Chattopadhyay Sanat (Exe V-P & Pres. MMD) has filed a Form 3 on Merck & Co., Inc. |